Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

• Published in: Blood Vol. 116; no. 3; pp. 406 - 417
• Main Authors: Kikuchi, Jiro, Wada, Taeko, Shimizu, Rumi, Izumi, Tohru, Akutsu, Miyuki, Mitsunaga, Kanae, Noborio-Hatano, Kaoru, Nobuyoshi, Masaharu, Ozawa, Keiya, Kano, Yasuhiko, Furukawa, Yusuke
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 22.07.2010; Americain Society of Hematology
• Subjects: Animals; Apoptosis - drug effects; Biological and medical sciences; Boronic Acids - administration & dosage; Boronic Acids - therapeutic use; Bortezomib; Caspase 8 - metabolism; Cell Line, Tumor; Depsipeptides - administration & dosage; Down-Regulation - drug effects; Drug Synergism; Gene Knockdown Techniques; Hematologic and hematopoietic diseases; Histone Deacetylase 1 - genetics; Histone Deacetylase Inhibitors - administration & dosage; Histone Deacetylase Inhibitors - therapeutic use; Histone Deacetylases - classification; Histone Deacetylases - genetics; Histone Deacetylases - metabolism; Humans; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunopathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma - drug therapy; Multiple Myeloma - enzymology; Multiple Myeloma - genetics; Multiple Myeloma - pathology; Pyrazines - administration & dosage; Pyrazines - therapeutic use; RNA, Small Interfering - genetics; Sp1 Transcription Factor - metabolism; Xenograft Model Antitumor Assays; Antineoplastic agent; Immunopathology; Histone deacetylase; Bortezomib; Targeting; Hematology; Cytotoxicity; Malignant hemopathy; Myeloma; Immunoglobulinopathy; Analog; Proteasome inhibitor; Lymphoproliferative syndrome; Dipeptides; Cancer

Bortezomib is now widely used for the treatment of multiple myeloma (MM); however, its action mechanisms are not fully understood. Despite the initial results, recent investigations have indicated that bortezomib does not inactivate nuclear factor-κB activity in MM cells, suggesting the presence of...